Jul. 7 at 12:18 PM
$JSPR On July 7, 2025, reported updated data from its BEACON Phase 1b/2a study of briquilimab in adult participants with chronic spontaneous urticaria. The study showed promising results, with 89% of participants in the 240mg and 360mg single-dose cohorts achieving a complete response. However, issues with a specific drug product lot affected results in some cohorts, leading to the halting of the ETESIAN study in asthma and a pause in development for SCID. Jasper plans to enroll additional patients to ensure robust data for future studies and is implementing cost-cutting measures to extend its financial runway.
The most recent analyst rating on stock is a Buy with a
$80.00 price target. To see the full list of analyst forecasts on Jasper Therapeutics stock, see the JSPR
